共 50 条
- [1] First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results from the solid tumors cohort.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Chen, L. C.Rosen, L. S.Iyengar, T.Goldman, J. W.Savage, R.Kazakin, J.Chan, T. C. K.Schwartz, B. E.Abbadessa, G.Von Hoff, D. D.
- [2] Therapeutic potential of ARQ 621, a novel Eg5 kinesin inhibitor with low bone marrow toxicityCANCER RESEARCH, 2009, 69Chen, Chang-RungAli, SyedUppalapati, UmaSavage, RonWang, ChiWaghorne, CarolAshwell, MarkChan, ThomasGoldstein, RobinFrance, Dennis
- [3] Translational development of the novel kinesin spindle protein (KSP/Eg5) inhibitor SB-743921 (SB-921) in lymphoma: from preclinical models to phase 1 studiesEJC SUPPLEMENTS, 2008, 6 (12): : 128 - 128Zain, D.Bongero, D.Goy, A.Orlowski, R.Hainsworth, J.Afanasyev, B.Chen, M. M.Escandon, R.Mao, Y.O'Connor, O. A.
- [4] Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-InhibitorBLOOD, 2015, 126 (23)Harb, WaelSaleh, Mansoor N.Papadopoulos, Kyriakos P.Chai, FengLarmar, MariaAbbadessa, GiovanniSchwartz, BrianTolcher, Anthony
- [5] Characterization and preclinical development of LCI-1, a selective and potent Chk1 inhibitor in phase 1 clinical trialsMOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)Marshall, MarkBarda, DavidBarnard, DarleneCox, KarenDiaz, H. BruceKing, ConstanceNutter, SuzanneWestin, Eric
- [6] A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2014, 74 : 15 - 23Hiroshi WakuiNoboru YamamotoSatoru KitazonoHidenori MizugakiShinji NakamichiYutaka FujiwaraHiroshi NokiharaYasuhide YamadaKohei SuzukiHironori KandaShiro AkinagaTomohide Tamura
- [7] Regorafenib for gastrointestinal malignancies: From preclinical data to clinical results of a novel multi-target inhibitorBioDrugs, 2013, 27 (3) : 213 - 224Aprile G.MacErelli M.Giuliani F.
- [8] A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumorsCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 15 - 23Wakui, HiroshiYamamoto, NoboruKitazono, SatoruMizugaki, HidenoriNakamichi, ShinjiFujiwara, YutakaNokihara, HiroshiYamada, YasuhideSuzuki, KoheiKanda, HironoriAkinaga, ShiroTamura, Tomohide
- [9] BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical developmentCANCER RESEARCH, 2019, 79 (13)Keegan, MitchellWilcoxen, KeithHo, Peter T.
- [10] Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical StudyPLOS ONE, 2016, 11 (10):Bekker, PirowDairaghi, DanielSeitz, LisaLeleti, ManmohanWang, YuErtl, LindaBaumgart, TrageenShugarts, SarahLohr, LisaDang, TonMiao, ShichangZeng, YibinFan, PingchenZhang, PenglieJohnson, DanielPowers, JayJaen, JuanCharo, IsraelSchall, Thomas J.